SHERWOOD MEDICAL'S FIRST INTRASCOPIC MINIMALLY INVASIVE DEVICES will be introduced at the beginning of the second quarter, the firm says March 1 in announcing its entry into the new line of business. The recently cleared line of laparoscopic irrigation and electrocautery systems was developed by Miami-based Symbiosis, which Sherwood Medical parent American Home Products purchased last September ("The Gray Sheet" Sept. 28, p. 3). The devices will be marketed by the newly developed Sherwood Intrascopic division. Sherwood Medical said in the press release that the Intrascopic division "will be responsible for the company's entry into the rapidly growing minimally invasive surgery market." Robert Egan is vice president and general manager of the new division. The unit, which will operate out of St. Louis where Sherwood is headquartered, currently has approximately 15 employees, including a sales force that exclusively will market Sherwood Intrascopic products. The firm notes that the division is not yet completely staffed. Sherwood Medical says that the development of the new division occurred independently of AHP's acquisition of Symbiosis, which also currently manufactures minimally invasive surgical instruments for Johnson & Johnson's Ethicon Endo-Surgery Division and for Boston Scientific. Sherwood Medical says that Symbiosis will continue to operate as an independent AHP subsidiary, marketing its products through Sherwood Intrascopic as well as other entities. Symbiosis is expected to be one of several sources for Intrascopic division products. Sherwood Medical notes that it continues to pursue "cost effective technologies, both internally and externally, in order to continue developing innovative products" for the Intrascopic division.
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
The US FDA has launched the Regulatory Accelerator to expedite digital health product development. This includes resources like a Resource Index for Innovators, a Medical Device Software Guidance Navigator, and best practices for early meetings.
In his first 100 days as FDA commissioner, Martin Makary has gone from vocal critic to vocal supporter of the agency’s staff, calling them “phenomenal” and praising their dedication—even as morale remains shaken by recent layoffs and restructuring.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
